Business
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster potentialReaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Lt
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"Teva Pharmaceutical Industries Ltd","displaySize":"","headline":null,"caption":"Teva Pharmaceutical Industries Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vrlzyJKRPwSh_YtGafCgLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Teva outlines acceleration path into a leading biopharma company","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster potential","length":200,"tagName":"p"}]},{"val":[{"type":"text","content":"Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs","length":130,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":394,"olType":false},{"type":"text","content":"TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The event, led by President and CEO Richard Francis and members of Teva’s executive management team, will outline the company’s strategy, progress and roadmap to deliver sustained shareholder value through 2030 and beyond.","length":565,"tagName":"p"},{"type":"text","content":"Presentations begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.","length":276,"tagName":"p"},{"type":"text","content":"Where We Are TodayTeva has completed Phase 1 of the Strategy: Return to Growth, delivering:","length":92,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":...